Choice of initial combination antiretroviral therapy in individuals with HIV infection determinants and outcomes

Archives of Internal Medicine

Volumn 172, Issue 17, 2012, Pages 1313-1321

  Elzi, Luigia ^a   Erb, Stefan ^a   Furrer, Hansjakob ^b   Ledergerber, Bruno ^c   Cavassini, Matthias ^d   Hirschel, Bernard ^e   Vernazza, Pietro ^f   Bernasconi, Enos ^g   Weber, Rainer ^c   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Cantonal Hospital S Gallen   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; COTRIMOXAZOLE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG CHOICE; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OPIATE SUBSTITUTION TREATMENT; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD;

EID: 84867152362     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.3216     Document Type: Article

References (42)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
2. Egger M, May M, Chêne G, et al ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-129. (Pubitemid 34786200)
3. May M, Sterne JA, Sabin C, et al Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185-1197. (Pubitemid 46763289)
4. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997;315(7117):1194-1199. (Pubitemid 27478210)
5. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685-692. (Pubitemid 46568625)
6. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65-71. (Pubitemid 351228129)
7. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, January 2011. http://aidsinfo.nih.gov/guidelines. Accessed February 14, 2011.
8. Thompson MA, Aberg JA, Cahn P, et al International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
9. El-Sadr WM, Lundgren JD, Neaton JD, et al Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296. (Pubitemid 44837777)
10. Emery S, Neuhaus JA, Phillips AN, et al Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133-1144. (Pubitemid 351590049)
11. Kaufmann GR, Elzi L, Weber R, et al. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS. 2011;25(4):441-451.
12. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632-1641. (Pubitemid 44232373)
13. Elzi L, Marzolini C, Furrer H, et al Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57-65.
14. Brouwer ESNS, Eron JJ. Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral regimen: evidence of channeling bias in HIV clinical care. Paper presented at: 5th International Aids Society Conference on HIV Pathogenesis Treatment and Prevention; February 14, 2011; Cape Town, South Africa. Abstract TUPEB117.
15. Wandeler G, Keiser O, Hirschel B, et al Swiss HIV Cohort Study. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One. 2011;6(12):e27903. doi:10.1371/journal.pone.0027903.
16. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al Swiss HIV Cohort Study. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010;39(5):1179-1189.
17. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
18. Department of Health and Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nihgov/guidelines. Accessed February 14, 2011.
19. Keiser O, Gayet-Ageron A, Rudin C, et al Swiss HIV Cohort Study (SHCS); Swiss Mother & Child HIV Cohort Study (MoCHiV). Antiretroviral treatment during pregnancy. AIDS. 2008;22(17):2323-2330.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(suppl 1):S62-S69.
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847. (Pubitemid 28213628)
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
24. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
25. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714-721.
26. Riddler SA, Haubrich R, DiRienzo AG, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl JMed. 2008;358(20):2095-2106. (Pubitemid 351679596)
27. von Wyl V, Yerly S, Böni J, et al; for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med. 2007;167(16):1782-1790. (Pubitemid 47403067)
28. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25(18):2301-2304.
29. Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2008;9(1):1-10. (Pubitemid 351214236)
30. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50(5):474-481.
31. Molina JM, Andrade-Villanueva J, Echevarria J, et al CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655.
32. Molina JM, Andrade-Villanueva J, Echevarria J, et al CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-332.
33. Lang S, Mary-Krause M, Cotte L, et al Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170(14):1228-1238.
34. Gallant JE, DeJesus E, Arribas JR, et al Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260. (Pubitemid 43113030)
35. DeJesus E, Herrera G, Teofilo E, et al; CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038-1046. (Pubitemid 39313463)
36. Sax PE, Tierney C, Collier AC, et al; AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191-1201.
37. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49-57.
38. Sax PE, Tierney C, Collier AC, et al; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-2240.
39. Smith KY, Patel P, Fine D, et al HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):1547-1556.
40. 3 in Mexico. J Acquir Immune Defic Syndr. 2010;53(5):582-588.
41. Yerly S, Junier T, Gayet-Ageron A, et al Swiss HIV Cohort Study. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS. 2009;23(11):1415-1423.
42. Rauch A, Nolan D, Thurnheer C, et al Swiss HIV Cohort Study. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther. 2008;13(8):1019-1028.